| Name | erythropoietin |
|---|---|
| Synonyms | EP; EPO; Epoetin; Erythropoietin; Erythropoietin precursor; Epoetins; Erythropoietins; Erythropoietin precursors |
| Name | ferrous sulfate |
|---|---|
| CAS | sulfuric acid iron(2+) salt (1:1) |
| PubMed | Abstract | RScore(About this table) | |
|---|---|---|---|
| 9550669 | Duranay M, Bali M, Sahin M, Yakinci G, Vurgun N, Dilmen U: Parvovirus B19 infection and unresponsiveness to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant. 1998 Mar;13(3):779-80. |
1(0,0,0,1) | Details |
| 9115299 | Melillo G, Taylor LS, Brooks A, Musso T, Cox GW, Varesio L: Functional requirement of the hypoxia-responsive element in the activation of the inducible synthase promoter by the iron chelator desferrioxamine. J Biol Chem. 1997 May 2;272(18):12236-43. The iron chelator desferrioxamine (DFX) induces the activity of the human erythropoietin enhancer in Hep3B cells. |
1(0,0,0,1) | Details |
| 15212134 | Williams M, Blocksom JM, Baciewicz FA Jr: Coronary artery bypass grafting in a dialysis-dependent Jehovah's Witness. Tex Heart Inst J. 2004;31(2):181-3; discussion 183. Coronary artery bypass grafting can be performed safely in the Jehovah's Witness patient with dialysis-dependent chronic renal failure by performing the operation electively if possible, limiting blood loss through the application of off-pump bypass and autologous transfusion techniques during surgery, increasing hemoglobin during both the pre- and postoperative periods by using erythropoietin and ferrous sulfate, and maintaining delivery during the postoperative period by the use of inotropic agents. |
31(0,1,1,1) | Details |
| 10850644 | Skikne BS, Ahluwalia N, Fergusson B, Chonko A, Cook JD: Effects of erythropoietin therapy on iron absorption in chronic renal failure. J Lab Clin Med. 2000 Jun;135(6):452-8. The absorption of 50 mg of iron as ferrous sulfate increased 2.4-fold from 3.8% to 9.4% (P < .05) when given without food and 4.2-fold from 1.4% to 5.9% (P < .05) when given with food after erythropoietin administration. |
15(0,0,1,10) | Details |
| 7677965 | Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW: Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med. 1993 Jan 14;328(2):73-80. |
8(0,0,0,8) | Details |
| 17338998 | Beck-da-Silva L, Rohde LE, Pereira-Barretto AC, de Albuquerque D, Bocchi E, Vilas-Boas F, Moura LZ, Montera MW, Rassi S, Clausell N: Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia. J Card Fail. 2007 Feb;13(1):14-7. Many studies have investigated the effects of treating anemia in HF patients with either erythropoietin alone or combination of erythropoietin and intravenous iron. Interventions are iron intravenously 200 mg once per week for 5 weeks, ferrous sulfate 200 mg by mouth 3 times per day for 8 weeks, or placebo. |
1(0,0,0,1) | Details |
| 2299254 | Goodnough LT, Brittenham GM: Limitations of the erythropoietic response to serial phlebotomy: implications for autologous blood donor programs. J Lab Clin Med. 1990 Jan;115(1):28-35. This report also indicates that a significant number of AB units have red cell volumes below minimum standards for blood donation, which has important implications in a risk/benefit analysis of whether nontransfused AB units should be "crossed-over" for HB transfusion, and that future studies designed to maximize AB procurement should include an evaluation of recombinant erythropoietin therapy in AB programs and therapeutic alternatives to ferrous sulfate as iron supplementation in AB donors. |
7(0,0,1,2) | Details |
| 12481145 | Trivedi HS, Brooks BJ: Erythropoietin therapy in pre-dialysis patients with chronic renal failure: lack of need for parenteral iron. Am J Nephrol. 2003 Mar-Apr;23(2):78-85. |
7(0,0,0,7) | Details |
| 10778761 | Smaniotto D, Luzi S, Morganti AG, Cellini N: Prognostic significance of anemia and role of erythropoietin in radiation therapy. Tumori. 2000 Jan-Feb;86(1):17-23. The results of a series of clinical studies published in the last decade allow some general observations: 1. the administration of erythropoietin, especially if associated to ferrous sulfate is able to increase hemoglobulin levels in cancer patients undergoing radiation therapy (combined with concomitant chemotherapy); 2. erythropoietin stimulation of hemoglobin in anemia decreases the need for blood transfusion in cancer patients; 3. tumor response to radiation therapy appears to be enhanced by erythropoietin-induced hemoglobulin increase. |
7(0,0,1,2) | Details |
| 1542922 | Biesma DH, Kraaijenhagen RJ, Poortman J, Marx JJ, van de Wiel A: The effect of oral iron supplementation on erythropoiesis in autologous blood donors. Transfusion. 1992 Feb;32(2):162-5. During the preoperative period, in which 4 units of blood were collected, 17 patients received oral iron supplementation with 287 mg of ferrous sulfate (105 mg of elemental iron/day), while 17 patients did not use any iron supplementation. In both iron-supplemented and control patients, serum erythropoietin levels returned to initial values within a few days after surgery. |
1(0,0,0,1) | Details |
| 8171147 | Polley JW, Berkowitz RA, McDonald TB, Cohen M, Figueroa A, Penney DW: Craniomaxillofacial surgery in the Jehovah's Witness patient. Plast Reconstr Surg. 1994 May;93(6):1258-63. A management protocol was developed utilizing preoperative erythropoietin and ferrous sulfate therapy, intraoperative in-line normovolemic hemodilution, and meticulous intraoperative hemostasis which allows us to perform major craniomaxillofacial reconstructions in Jehovah's Witness patients without the use of homologous or predonated autologous blood transfusions. |
6(0,0,1,1) | Details |
| 8083076 | Dusenbery KE, McGuire WA, Holt PJ, Carson LF, Fowler JM, Twiggs LB, Potish RA: Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1079-84. Fifteen were treated with r-HuEPO (200 U/kg/day) and ferrous sulfate 5-10 days prior to initiation of external beam radiation therapy, continuing until Hgb was < or = 14 g/dL or completion of radiation therapy. |
4(0,0,0,4) | Details |
| 8459128 | Masai T, Sakakibara T, Watanabe S, Akedo H, Furutani Y, Kodama K: [2 cases report of open heart surgery with non-blood transfusion in severe valvular heart disease with cardiac cachexia--the efficacy of recombinant human erythropoietin]. Nippon Kyobu Geka Gakkai Zasshi. 1993 Jan;41(1):105-10. Both patients were administered 9000-18000 U/week of EPO and ferrous sulfate pre- and postoperatively. |
1(0,0,0,1) | Details |
| 7872321 | Wingard RL, Parker RA, Ismail N, Hakim RM: Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis. 1995 Mar;25(3):433-9. These four preparations included Chromagen (ferrous Savage Laboratories, Melville, NY), Feosol (ferrous sulfate; SmithKline Beecham, Inc, Pittsburgh, PA), Niferex (polysaccharide; Central Pharmaceuticals, Inc, Seymour, IN), or Tabron (ferrous Parke-Davis, Morris Plains, NJ). |
4(0,0,0,4) | Details |
| 11252534 | Markova M, Haluzik M, Svobodova J, Rosicka M, Nedvidkova J, Haas T: Serum leptin levels in patients with sideropenic and pernicious anemia: the influence of anemia treatment. Physiol Res. 2000;49(6):679-84. The aim of our study was to measure serum leptin and erythropoietin levels in patients with sideropenic (n = 18) and pernicious anemia (n=7) before and during anemia treatment. |
4(0,0,0,4) | Details |
| 9756115 | Bhandari S, Brownjohn A, Turney J: Effective utilization of erythropoietin with intravenous iron therapy. J Clin Pharm Ther. 1998 Feb;23(1):73-8. |
3(0,0,0,3) | Details |
| 8967587 | Soukup J, Menzel M, Roth S, Radke J: [The perioperative use of recombinant erythropoietin (rhEPO) in Jehovah's witnesses]. Anaesthesist. 1996 Aug;45(8):745-9. After preoperative subcutaneous application of 5000 I.E. rhEPO three times per week and daily oral substitution of 300 mg ferrous sulfate over a period of 3 weeks, the Hb increased to 15.5 g/dl and the HCt to 49%. |
3(0,0,0,3) | Details |
| 12118656 | Kalu E, Wayne C, Croucher C, Findley I, Manyonda I: Triplet pregnancy in a Jehovah's witness: recombinant human erythropoietin and iron supplementation for minimising the risks of excessive blood loss. BJOG. 2002 Jun;109(6):723-5. |
1(0,0,0,1) | Details |
| 14655280 | Markova M, Haluzik M, Jiskra J, Haluzikova D, Svobodova J, Rosicka M: [Effect of sideropenic anemia and its therapy on serum levels of leptin] . Cas Lek Cesk. 2001 Dec 6;140(24):767-9. Blood count, serum leptin, erythropoietin (EPO) and transpherine receptor (TfR) levels were estimated in all samples. |
1(0,0,0,1) | Details |
| 17448971 | Cuenca J, Garcia-Erce JA, Martinez F, Cardona R, Perez-Serrano L, Munoz M: Preoperative haematinics and transfusion protocol reduce the need for transfusion after total knee replacement. Int J Surg. 2007 Apr;5(2):89-94. Epub 2006 Apr 27. CONCLUSION: This protocol seems to be effective for avoiding ABT in non-anaemic TKR patients, whereas for anaemic patients another blood saving strategy, such us preoperative erythropoietin administration or postoperative blood salvage, should be added to further increase its effectiveness. |
1(0,0,0,1) | Details |
| 11465435 | Christopoulou M, Derartinian H, Hatzidimitriou G, Iatrou L: Autologous blood transfusion in oral and maxillofacial surgery patients with the use of erythropoietin. J Craniomaxillofac Surg. 2001 Apr;29(2):118-25. |
3(0,0,0,3) | Details |
| 7771487 | Shrivastava D, Rao TK, Sinert R, Khurana E, Lundin AP, Friedman EA: The efficacy of erythropoietin in human immunodeficiency virus-infected end-stage renal disease patients treated by maintenance hemodialysis. Am J Kidney Dis. 1995 Jun;25(6):904-9. |
3(0,0,0,3) | Details |
| 9297428 | Javier Manchon G, Natal Pujol A, Coroleu Lletget W, Zuasnabar Cotro A, Badia Barnusell J, Junca Piera J, Bel Comos J, Sabado Alvarez C, Prats Vinas J: [Randomized multi-center trial of the administration of erythropoietin in anemia of prematurity]. An Esp Pediatr. 1997 Jun;46(6):587-92. Those infants ascribed to the treatment group received 200 U/kg of body weight of rH-EPO subcutaneously once a day, three days a week for 4 weeks together with oral supplements of ferrous sulfate at a dosage of 4 mg/kg/day. |
3(0,0,0,3) | Details |
| 1431504 | Skikne BS, Cook JD: Effect of enhanced erythropoiesis on iron absorption. J Lab Clin Med. 1992 Nov;120(5):746-51. To examine the influence of erythropoiesis on iron absorption, radioiron absorption tests were performed in normal subjects before and after a course of recombinant erythropoietin. The absorption of heme and nonheme iron from a standard meal was measured in nine subjects, and the absorption of a therapeutic dose of ferrous sulfate given with or without food was determined in an additional 11 subjects. |
3(0,0,0,3) | Details |
| 11887827 | Johnson DW, Herzig KA, Gissane R, Campbell SB, Hawley CM, Isbel NM: Oral versus intravenous iron supplementation in peritoneal dialysis patients. Perit Dial Int. 2001;21 Suppl 3:S231-5. The vast majority of erythropoietin (EPO)-treated peritoneal dialysis (PD) patients require iron supplementation. |
1(0,0,0,1) | Details |
| 10343955 | Antunes I, Resende C, Granjo E, Mesquita-Guimares J: Recombinant human erythropoietin alpha in the correction of anaemia in epidermolysis bullosa. J Eur Acad Dermatol Venereol. 1999 Mar;12(2):181-2. |
1(0,0,0,1) | Details |
| 2757026 | Van Wyck DB: management during recombinant human erythropoietin therapy. Am J Kidney Dis. 1989 Aug;14(2 Suppl 1):9-13. In all patients except those with transfusional iron overload, prophylactic supplementation with ferrous sulfate (325 mg up to three times daily) is recommended. |
2(0,0,0,2) | Details |
| 8659499 | Silverberg DS, Iaina A, Peer G, Kaplan E, Levi BA, Frank N, Steinbruch S, Blum M: Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis. 1996 Feb;27(2):234-8. Iron deficiency may develop in hemodialysis patients, especially when erythropoietin is given. |
2(0,0,0,2) | Details |
| 8600865 | Green D, Lawler M, Rosen M, Bloom S, Duerden M, Turba R, Kern H, Kirschner K, Ronin D: Recombinant human erythropoietin: effect on the functional performance of anemic orthopedic patients. Arch Phys Med Rehabil. 1996 Mar;77(3):242-6. All patients received ferrous sulfate. |
2(0,0,0,2) | Details |
| 8428002 | Brugnara C, Chambers LA, Malynn E, Goldberg MA, Kruskall MS: Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: iron-deficient erythropoiesis in iron-replete subjects. Blood. 1993 Feb 15;81(4):956-64. All healthy subjects took oral ferrous sulfate. |
2(0,0,0,2) | Details |
| 12640375 | Juul SE, Zerzan JC, Strandjord TP, Woodrum DE: /heme as an indicator of iron status in NICU patients. J Pediatr. 2003 Mar;142(3):273-8. Gestational age, growth variables, iron supplementation, erythropoietin treatment, and blood transfusions were documented. |
2(0,0,0,2) | Details |
| 7934135 | Stone RM, Bernstein SH, Demetri G, Facklam DP, Arthur K, Andersen J, Aster JC, Kufe D: Therapy with recombinant human erythropoietin in patients with myelodysplastic syndromes. Leuk Res. 1994 Oct;18(10):769-76. Ferrous sulfate (325 mg po tid) was also administered if the transferrin saturation was below 30% (two patients). |
2(0,0,0,2) | Details |
| 19469261 | Nikitin EN, Krasnoperova OV, Nikitin IuE: [Experience in the treatment of iron deficiency anemia with ferro-folgamma]. Klin Med. 2009;87(3):64-7. Criteria for the efficiency were changes in clinical symptoms of anemia, hemoglobin level, erythrocyte and reticulocyte counts, packed cell volume, erythrocyte indices (mean erythrocyte volume, average content and concentration of hemoglobin in erythrocytes), erythropoietin level, and characteristics of iron metabolism (serum iron and ferritin levels, total iron-binding capacity of the serum, coefficient of ferritin saturation with iron), and drug tolerance. |
2(0,0,0,2) | Details |
| 8417806 | Nagel RL, Vichinsky E, Shah M, Johnson R, Spadacino E, Fabry ME, Mangahas L, Abel R, Stamatoyannopoulos G: F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study. Blood. 1993 Jan 1;81(1):9-14. |
2(0,0,0,2) | Details |
| 7531047 | Kubanek B, Rich I, Noe G: [Erythropoietin] . Infusionsther Transfusionsmed. 1994 Nov;21 Suppl 3:46-50. A high dose of oral ferrous sulfate (300 mg) was given 11 days in advance of rHu EPO. |
2(0,0,0,2) | Details |
| 11328902 | Stoves J, Inglis H, Newstead CG: A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant. 2001 May;16(5):967-74. |
2(0,0,0,2) | Details |
| 8411806 | Inatsuchi H, Tanaka M, Masuda A, Arihara K, Katsuoka Y: [Preoperative collection of autologous blood with recombinant human erythropoietin therapy]. Nippon Hinyokika Gakkai Zasshi. 1993 Aug;84(8):1450-5. All the patients were given ferrous sulfate 100 mg of iron orally every day. |
2(0,0,0,2) | Details |
| 8262840 | Lavey RS, Dempsey WH: Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys. 1993 Dec 1;27(5):1147-52. All 40 patients were given oral ferrous sulfate throughout their radiation therapy course. |
2(0,0,0,2) | Details |
| 7529455 | Bourantas KL, Georgiou I, Seferiadis K: Fetal globin stimulation during a short-term trial of erythropoietin in HbS/beta-thalassemia patients. Acta Haematol. 1994;92(2):79-82. |
2(0,0,0,2) | Details |
| 2709674 | Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA: status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int. 1989 Feb;35(2):712-6. During acute rHuEPO therapy net body iron balance remained neutral in patients receiving no iron supplements and increased 5 mg/kg in patients prescribed oral ferrous sulfate. |
2(0,0,0,2) | Details |
| 7608597 | Shinonaga M: [Changes in hematological indices, iron levels and marrow erythroids through autologous blood donation before cardiac surgery--predonation with versus without recombinant human erythropoietin]. Nippon Kyobu Geka Gakkai Zasshi. 1995 Apr;43(4):479-87. A unit of autologous blood (200 ml) was to be donated every 3 or 4 days for 2 weeks. 200mg of ferrous sulfate was given orally every day in 10 patients (the simple donation group), while 200 U/kg of rEPO was given intravenously 3 times a week in combination with oral ferrous sulfate supplementation in 15 patients (the rEPO-treatment group). |
2(0,0,0,2) | Details |
| 11083968 | de la Torre Aguilar M, Gascon Jimenez FJ, Zapatero Martinez M, Guzman Cabanas J, Huertas Munoz D, Ruiz Gonzalez D, Jaraba Caballero P: [Prophylaxis of anemia of prematurity with erythropoietin. An Esp Pediatr. 2000 Sep;53(3):243-8. A ferrous sulfate supplement was also administered orally (4-6 mg/kg/day) with a multivitamin complex. |
2(0,0,0,2) | Details |
| 1680462 | Bender FH, Piraino B: Polycythemia in diabetic patients on CAPD. Adv Perit Dial. 1991;7:77-80. Prior to the development of polycythemia, ferritin levels were low and ferrous sulfate therapy was begun at a time the Hct values were 36 to 40%. Erythropoietin levels were obtained in 2 patients, and were 22 U/L (Hct 51%) and less than 5 U/L (Hct 55%). |
1(0,0,0,1) | Details |
| 18098311 | Skoner JM, Wax MK: Microvascular free-tissue transfer for head and neck reconstruction in Jehovah's Witness patients. Head Neck. 2008 Apr;30(4):455-60. supplements and/or erythropoietin were administered perioperatively in 6 of the 7 microvascular reconstructions. |
1(0,0,0,1) | Details |
| 16917084 | Bailey DM, Robach P, Thomsen JJ, Lundby C: Erythropoietin depletes iron stores: antioxidant neuroprotection for ischemic stroke? Stroke. 2006 Oct;37(10):2453. Epub 2006 Aug 17. |
1(0,0,0,1) | Details |
| 11045266 | Ahsan N: Infusion of total dose iron versus oral iron supplementation in ambulatory peritoneal dialysis patients: a prospective, cross-over trial. Adv Perit Dial. 2000;16:80-4. The study design included an oral phase [4 months, ferrous sulfate 325 mg (195 mg elemental iron), three times daily], a "wash-out" phase (1 month, no iron supplementation), and an ITDI phase [4 months, single infusion over 4 hours of 1 g iron dextran mixed in 1/2 normal saline]. Laboratory parameters were monitored monthly, and subcutaneous recombinant human erythropoietin (rHuEPO) doses were adjusted monthly to maintain a hematocrit above 33%. |
1(0,0,0,1) | Details |
| 7634987 | Demirturk L, Hulagu S, Yaylaci M, Altin M, Ozel M: Serum erythropoietin levels in patients with severe anemia secondary to inflammatory bowel disease and the use of recombinant human erythropoietin in patients with anemia refractory to treatment. Dis Colon Rectum. 1995 Aug;38(8):896-7. |
1(0,0,0,1) | Details |
| 9247787 | Kotaki M, Uday K, Henriquez M, Blum S, Dave M: Maintenance therapy with intravenous iron in hemodialysis patients receiving erythropoietin. Clin Nephrol. 1997 Jul;48(1):63-4. |
1(0,0,0,1) | Details |
| 14769316 | Kourtzis N, Pafilas D, Kasimatis G: Blood saving protocol in elective total knee arthroplasty. Am J Surg. 2004 Feb;187(2):261-7. It is based on perioperative administration of human recombinant erythropoietin plus iron and mild acute normovolemic hemodilution, meticulous surgical technique, postoperative blood salvage through a closed-wound drainage system, and lower transfusion triggers. |
1(0,0,0,1) | Details |
| 9328369 | Ahluwalia N, Skikne BS, Savin V, Chonko A: Markers of masked iron deficiency and effectiveness of EPO therapy in chronic renal failure. Am J Kidney Dis. 1997 Oct;30(4):532-41. Recombinant erythropoietin (rHuEPO) is well established in the management of anemia of chronic renal disease. |
1(0,0,0,1) | Details |
| 11214425 | Podesta A, Carmagnini E, Parodi E, Dottori V, Crivellari R, Barberis L, Audo A, Lijoi A, Passerone G: Elective coronary and valve surgery without blood transfusion in patients treated with recombinant human erythropoietin (epoetin-alpha). Minerva Cardioangiol. 2000 Nov;48(11):341-7. |
1(0,0,0,1) | Details |
| 8723587 | Gombotz H: Subcutaneous epoetin alfa as an adjunct to autologous blood donation before elective coronary artery bypass graft surgery. Semin Hematol. 1996 Apr;33(2 Suppl 2):69-70; discussion 71-2. Recombinant human erythropoietin (rHuEPO) has been used to facilitate AB donation and minimize the accompanying decrease in Hb levels in patients scheduled for cardiac surgery. |
1(0,0,0,1) | Details |
| 11990314 | Athanasiou-Metaxa M, Economou M, Tsantali C, Koussi A, Gombakis N: Congenital erythrocytosis with increased erythropoietin level. J Pediatr Hematol Oncol. 2002 Mar-Apr;24(3):234-6. |
1(0,0,0,1) | Details |
| 10873876 | Goicoechea M, Caramelo C, Ochando A, Andrea C, Garvia R, Ortiz A: Antiplatelet therapy alters iron requirements in hemodialysis patients. Am J Kidney Dis. 2000 Jul;36(1):80-7. Hemodialysis (HD) patients are prone to develop iron deficiency because of consumption of iron stores during erythropoietin (EPO) therapy. |
1(0,0,0,1) | Details |
| 10516989 | Yamaguchi T, Baxter JG, Maebashi N, Asano T: Oral binders: binding capacity of iron (III) complexes containing saccharides and their effect on the urinary excretion of and in rats. Ren Fail. 1999 Sep;21(5):453-68. binders that contain aluminum or are frequently prescribed to treat hyperphosphatemia in patients with end-stage renal disease (ESRD), but an accumulation of aluminum can lead to encephalopathy, aluminum-related bone disease (ARBD) such as osteomalacia, anaemia, and resistance to erythropoietin, and accumulation can lead to hypercalcaemia. High concentrations are reduced in vitro and in vivo by a adsorption pill, which is synthesized by hydrolyzing ferrous sulfate in the presence of saccharides, to form an iron (III)-saccharide complex that is acid resistant and binds greater than iron (III) alone. |
1(0,0,0,1) | Details |
| 1361760 | Domoto DT, Martin KJ: Failure of CAPD patients to respond to an oral iron absorption test. Adv Perit Dial. 1992;8:102-4. CAPD patients require supplemental iron to maintain a response to erythropoietin. Serum irons were measured at baseline in a fasting state and repeated two hours after the ingestion of 325 mgs ferrous sulfate in five CAPD patients. |
1(0,0,0,1) | Details |
| 16253714 | Goshorn J, Youell TD: Darbepoetin alfa treatment for post-renal transplantation anemia during pregnancy. Am J Kidney Dis. 2005 Nov;46(5):e81-6. Darbepoetin alfa (Aranesp; Amgen Inc, Thousand Oaks, CA) is a unique erythropoiesis-stimulating protein that can be administered at an extended dosing interval relative to recombinant human erythropoietin because of its approximately 3-fold longer serum half-life. |
1(0,0,0,1) | Details |
| 18986010 | Factor KF: Anemia management in peritoneal dialysis patients: can an iron supplement maintain a normal transferrin saturation and hemoglobin level?. Adv Perit Dial. 2008;24:96-8. The primary cause of anemia in dialysis patients is inadequate production of erythropoietin (EPO) by the dysfunctional kidneys. |
1(0,0,0,1) | Details |